AZ and Amgen are seeking approval for tezepelumab for the treatment of severe asthma patients, based on results from the companies’ PATHFINDER clinical programme.
This includes data from the pivotal phase 3 NAVIGATOR trial, which demonstrated that tezepelumab achieved a 56% reduction in the annual asthma exacerbation (AAER) rate over 52 weeks in the overall patient population when added to standard of care (SoC).
